Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matilde Sinibaldi

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Journal of the National Cancer Institute|September 28, 2021
Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell MalignanciesCarlos A Garcia-Prieto, Lorea Villanueva, Alberto Bueno-Costa, et al.
Haematologica|May 9, 2020
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cellsMarika Guercio, Domenico Orlando, Stefano Di Cecca, et al.
Journal of Hematology & Oncology|December 19, 2024
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cellsMichele Pezzella, Concetta Quintarelli, Maria C Quadraccia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2024
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ MedulloblastomaRoselia Ciccone, Concetta Quintarelli, Antonio Camera, et al.
Nature Medicine|January 15, 2025
Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastomaConcetta Quintarelli, Francesca Del Bufalo, Maria Antonietta De Ioris, et al.
Nature Medicine|February 5, 2026
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseasesMarco Becilli, Markus Metzler, Claudia Bracaglia, et al.
The New England Journal of Medicine|April 5, 2023
GD2-CART01 for Relapsed or Refractory High-Risk NeuroblastomaFrancesca Del Bufalo, Biagio De Angelis, Ignazio Caruana, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of the National Cancer Institute|September 28, 2021
Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell MalignanciesCarlos A Garcia-Prieto, Lorea Villanueva, Alberto Bueno-Costa, et al.
Haematologica|May 9, 2020
CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cellsMarika Guercio, Domenico Orlando, Stefano Di Cecca, et al.
Journal of Hematology & Oncology|December 19, 2024
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cellsMichele Pezzella, Concetta Quintarelli, Maria C Quadraccia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2024
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ MedulloblastomaRoselia Ciccone, Concetta Quintarelli, Antonio Camera, et al.
Nature Medicine|January 15, 2025
Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastomaConcetta Quintarelli, Francesca Del Bufalo, Maria Antonietta De Ioris, et al.
Nature Medicine|February 5, 2026
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseasesMarco Becilli, Markus Metzler, Claudia Bracaglia, et al.
The New England Journal of Medicine|April 5, 2023
GD2-CART01 for Relapsed or Refractory High-Risk NeuroblastomaFrancesca Del Bufalo, Biagio De Angelis, Ignazio Caruana, et al.
Pageof 3